AIMV Signs Real Heal Access Deal After Retracting September Claim; $5M Note Plus 20M Shares, $6M Raise Required
AIMV has more than doubled off its 52-week low of $0.012 on light trading volume (0.1× avg).
Summary
AIMV finally signed the definitive share purchase agreement for Heal Access Canada on October 12, buying the agentic AI healthcare platform from HEAL Group Holdings, its own 77% controlling stockholder. The company also admitted its September 21 release claiming a signed definitive agreement was wrong — only a non-binding LOI existed at the time. Price is US$5M in cash, paid via a secured two-year promissory note at 10% interest, plus 20 million exchangeable shares convertible one-for-one into AIMV common; AIMV also assumes roughly US$6.4M Heal Access owes HEAL Group. Closing is not assured: it requires at least US$6M in new financing by December 31, 2026, special committee ratification, and an Investment Canada Act filing, with a February 28, 2027 outside date. The related-party structure is the key risk — HEAL Group would hold about 80.1% after exchange, Heal Access depends on a small number of customers several of which are HEAL Group affiliates, and the platform has a history of operating losses. For a sub-$1.2M market cap OTC shell, the $6M raise is the gating item; failure to fund kills the deal.
At the time of this announcement, AIMV was trading at $0.05 on OTC in the Technology sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.01 to $0.31. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.